IDEXX Laboratories, Inc.
HealthcareNASDAQ:IDXX · NASDAQ Global Select
+$1.46 today
Vol 0.23M · Avg 0.58M
Intrinsic Value
IDXX Intrinsic Value
Start with the valuation result. Compare the current market price with the system DCF estimate, then use the supporting sections below to decide whether the assumptions are reasonable.
Intrinsic Value
System DCF · consensus of 4 models
Sign in to unlock intrinsic value
Free accounts get 5 valuations per week. Upgrade for more.
Monitor IDXX
Get notified when the price moves into your range
Use alerts to turn the valuation into an action plan instead of checking the stock manually.
Price Alerts
Get notified when IDXX drops below a target
Sign in to activate price alerts · unlock IV-based targets
Valuation History
Is IDXX cheaper or more expensive than usual?
Review how the market has valued IDEXX Laboratories, Inc. over time before deciding whether today’s discount or premium is unusual.
Price History
Dividend-adjusted closing price
Change
+6.17%
Period High
$766.68
Period Low
$514.61
Latest
$559.42
Analyst Targets
See where analysts expect IDXX to trade next
Compare the latest consensus target range with the current share price to understand how much upside or downside Wall Street is pricing in.
Wall Street Price Targets
1-year price history with analyst consensus target
Current
$559.42
Low Target
$640.00
Avg Target
$747.50
High Target
$800.00
Upside (Avg)
+33.62%
Alternatives to IDXX
Compare IDEXX Laboratories, Inc. with similar companies
A stock can look attractive in isolation and still be less compelling than a peer. Check competitors before committing to the thesis.
Competitors
Peer companies in the same sector
argenx SE
NASDAQ:ARGX
$55.60B
Cencora, Inc.
NYSE:COR
$54.90B
Becton, Dickinson and Company
NYSE:BDX
$52.82B
Cardinal Health, Inc.
NYSE:CAH
$52.34B
Edwards Lifesciences Corporation
NYSE:EW
$48.80B
Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
$37.89B
Agilent Technologies, Inc.
NYSE:A
$36.54B
Zoetis Inc.
NYSE:ZTS
$33.66B
IQVIA Holdings Inc.
NYSE:IQV
$29.85B
Veeva Systems Inc.
NYSE:VEEV
$25.83B
Fundamental Analysis
Capture the investment case and test company quality
Write down the key idea, risks, and what would change your mind. Then review growth, profitability, returns, owner payouts, and insider activity.
My Notes
Journal entries for IDXX
Sign in to keep notes
Track your buy/sell/hold decisions for every stock in your personal journal.
Quality Snapshot
Start with the numbers that compound value
Check whether earnings, revenue, equity, cash, and returns on capital are moving in the same direction as your written thesis.
Big Five Numbers
CAGR by period · ROIC shows average
| Metric | 10yr | 5yr | 3yr | 1yr |
|---|---|---|---|---|
EPS | N/A | N/A | +8.8% | +14.5% |
Revenue | N/A | N/A | +7.4% | +7.8% |
Equity | +5.5% | N/A | N/A | +9.2% |
Cash | N/A | N/A | -16.8% | -60.0% |
ROIC | 25.7% | 32.8% | 36.1% | 41.8% |
Analysis
Latest growth is strongest in ROIC at 41.8% and weakest in Cash at -60.0%. Three-year average ROIC is 36.1%, which helps show whether that growth is being earned efficiently.
Growth Profile
Compare historical growth with forward expectations
Strong past growth matters more when analysts still expect the business to expand without relying on one temporary driver.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +8.8% | +18.5% (15yr)6 analysts |
| Revenue | N/A | N/A | +7.4% | +10.3% (15yr)5 analysts |
| Net Income | N/A | N/A | +2.5% | +17.3% (15yr)5 analysts |
| EBIT | N/A | N/A | +4.5% | +13.7% (15yr)5 analysts |
Analysis
Recent growth has been strongest in EPS at +8.8% over three years. Forward estimates point to EPS at +18.5% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Earnings Quality
Follow revenue through to net income
Use the waterfall to see which costs, margins, and operating lines explain how much of each sales dollar becomes profit.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$4.4B of revenue converted into $1.1B of net income for the selected period. Gross margin is 62.0% and net margin is 24.6%, showing how much revenue survives after costs and taxes. EPS is $13.56, tying the income statement back to per-share earnings.
Capital Efficiency
Measure how well IDEXX Laboratories, Inc. turns capital into returns
Returns on equity, invested capital, and assets help separate durable operators from businesses that only grow by adding more capital.
Return Metrics
ROE, ROIC & ROA over time
ROE
66.0%
avg -377.4%
ROIC
40.3%
avg 31.0%
ROA
31.6%
avg 23.3%
Analysis
ROE is currently the strongest return metric at 66.0% versus its period average of -377.4%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Owner Returns
Review how cash comes back to shareholders
Dividends, buybacks, and debt paydown show whether excess cash is being reinvested, returned, or used to strengthen the balance sheet.
Shareholder Returns
Dividend, buyback & debt paydown yields
Dividend Yield (TTM)
0.00%
Buyback Yield (TTM)
2.65%
Debt Paydown (TTM)
0.00%
Total Yield (TTM)
2.65%
Analysis
Total TTM shareholder yield is 2.65% including 0.00% from debt paydown. The largest current contributor is buybacks at 2.65%, which helps show whether capital returns are coming from direct cash payouts, share count reduction, or balance sheet cleanup.
Dividend Record
Check payout durability before counting on yield
A dividend is more useful when growth, payout ratio, and free cash flow support the current yield.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
2.76%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Company Overview
Understand how IDEXX Laboratories, Inc. makes money
Finish by grounding the numbers in the company profile, leadership, balance sheet, and free cash flow.
Key Information
Leadership
Put the business in management context
Company facts explain what IDEXX Laboratories, Inc. does; leadership context helps you judge who is responsible for capital allocation and execution.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jonathan J. Mazelsky | Executive Chairman | $3.78M | — | 65 | $0.00 | <0.01% |
Michael Erickson | President, Chief Executive Officer & Director | $3.78M | — | 52 | $14,229.35 | 0.02% |
Michael J. Lane | Executive Vice President and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology | $1.32M | — | 58 | $14,229.35 | 0.02% |
Nimrata Khatra Hunt | Advisor | $1.25M | — | 58 | $18,140.94 | 0.02% |
Martin Smith | Executive Vice President of Global Operations and R&D | $1.24M | — | 58 | $2,458.66 | <0.01% |
Andrew Emerson | Executive Vice President, Chief Financial Officer & Treasurer | $1.13M | — | 43 | $4,345.44 | <0.01% |
Sharon E. Underberg | Executive Vice President, General Counsel, & Corporate Secretary | $881,053.00 | — | 65 | $0.00 | <0.01% |
Amit Gupta | Senior VP, Chief Digital & Information Officer | — | — | — | — | — |
Eric Tracy | Senior Vice President Customer Experience | — | — | — | — | — |
Bob Asmann | Senior Vice President of Global Operations | — | — | — | — | — |
Daniel Janson | Senior VP & GM of Global Reference Laboratories | — | — | — | $525.00 | <0.01% |
George J. Fennell | Executive Vice President of Global CAG Commercial | — | — | 57 | $10,433.00 | 0.01% |
Jeffrey Carr | Senior Vice President, GM and Head of Product for Global Reference Labs & IBA | — | — | — | — | — |
Michael Johnson | Executive Vice President & Chief Human Resources Officer | — | — | 48 | $14,229.35 | 0.02% |
Michael Schreck | Executive VP & GM of Veterinary Software and Services, Corporate Accounts and Customer Experience | — | — | 58 | $14,229.35 | 0.02% |
Murthy Yerramilli | Senior VP of Assay and Instrument Research & Development | — | — | — | — | — |
Julie Godon | Senior Vice President & Global Marketing Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
23
$22.53M
Net Sentiment
$22.53M
Net selling
Most Active
MAZELSKY JONATHAN JAY
13 transactions
1–10 of 23
Analysis
Insiders reported 0 buys worth $0.00 and 23 sells worth $22.53M over the last 12 months. That adds up to net selling of $22.53M. MAZELSKY JONATHAN JAY was the most active insider with 13 transactions.
Financial Position
Check what supports the company underneath the income statement
The balance sheet shows liquidity, debt, asset mix, and book value quality before you rely on earnings or growth assumptions.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $200.5M |
| Receivables | $603.5M |
| Inventory | $382.4M |
| Other Current | $267.6M |
| Total Current Assets | $1.5B |
| PP&E (Net) | $740.4M |
| Goodwill | $412.1M |
| Intangible Assets | $104.8M |
| Other Non-current | $674.2M |
| Total Non-current Assets | $1.9B |
| Total Assets | $3.4B |
Analysis
Selected assets total $3.4B for Latest. The largest visible component is PP&E (Net) at $740.4M, about 21.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Cash Generation
Finish by testing whether profit turns into cash
Free cash flow connects accounting earnings to owner earnings, showing how much cash remains after reinvestment needs.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Explore More
Continue the stock analysis
Jump to another research area for this company.